Common Contracts
2 similar License Agreement contracts by Immune Design Corp.
ContractLicense Agreement • May 5th, 2020
EX-10.2 3 tvsdoc2.htm EXHIBIT 10.2 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Exhibit 10.2 LICENSE AGREEMENT THIS LICENSE AGREEMENT (this “Agreement”), dated as of October 17, 2016 (the “Execution Date”) and effective as of the Effective Date (as defined below), is entered into by and between Theravectys SA, a French société anonyme (“TVS”), and Immune Design Corp., a Delaware corporation (“IMDZ”) (with each of TVS and IMDZ being sometimes referred to herein, individually, as a “Party” and, collectively, as the “Parties”). WITNESSETH WHEREAS, TVS owns or controls, directly or indirectly, certain Licensed IP (as defined below) relating to lentiviral vector technology; WHEREAS, in connection with the execution and delivery of this Agreement, the Parties are entering into a Confidential Sett
LICENSE AGREEMENTLicense Agreement • March 3rd, 2017 • Immune Design Corp. • Pharmaceutical preparations
THIS LICENSE AGREEMENT (this “Agreement”), dated as of October 17, 2016 (the “Execution Date”) and effective as of the Effective Date (as defined below), is entered into by and between Theravectys SA, a French société anonyme (“TVS”), and Immune Design Corp., a Delaware corporation (“IMDZ”) (with each of TVS and IMDZ being sometimes referred to herein, individually, as a “Party” and, collectively, as the “Parties”).
